WASHINGTON (AP) — Shares of AstraZeneca and its partner Rigel Pharmaceuticals Inc. fell Thursday after the companies reported that their experimental rheumatoid arthritis drug was less effective than Abbott’s Humira in a midstage study.
Stay informed.Stay ahead.
Join Washington Examiner for unlimited access to the news, analysis, and commentary that matter most.
See Options
Already a member? Log in
Already a print subscriber? Click here to login/register your account
